According to Bloomberg, the seven research firms currently covering Akebia Therapeutics, INC (NASDAQ: AKBA) have given the stock an average rating of “Hold,” indicating that investors should continue to hold onto their shares.
This rating suggests that the stock is likely to remain relatively stable shortly. Only one of the analysts polled suggested buying the stock, but the other analysts all agreed it should be held steady at its current price.
The average one-year price target set by brokerages that have reported on the company in the preceding year is $1.75.
This target has been set by brokerages that have covered the company in the preceding year.
In other news about this topic, on March 1st, the Chief Executive Officer of the company, John P.
Butler, sold 91,868 of the company’s shares of stock.
The shares could be sold for a total of 80,843.84 dollars, equivalent to an average price of $0.88 per share.
As a result of the successful transaction completion, the CEO now owns 1,568,776 company shares, the total value of which is $1,380,607.36.
If you follow this link, you will be taken to the SEC filing in which the sale was disclosed.
Please click on the link to proceed.
During the most recent quarter of the company’s fiscal year, company insiders sold a total of 132,524 shares of company stock for a sum equal to $116,621.
Insiders, including employees and others working for the company, own 3.68% of the company’s total shares.
Many academic investigations have been carried out with AKBA as the primary focus.
The recommendation for Akebia Therapeutics was to “buy” the company’s stock in a research note published on Thursday, March 9th, by StockNews.com.
This recommendation was published in the note.
In a research report released on Friday, March 10th, HC Wainwright reaffirmed its “neutral” rating on shares of Akebia Therapeutics.
Additionally, the brokerage firm set a price objective of $1.25 for the company’s stock simultaneously.
During the most recent fiscal quarter, several significant investors changed how much AKBA stock they held in their portfolios.
Principal Financial Group INC increased the amount of Akebia Therapeutics stock owned by 124.1% during the year’s second quarter.
Principal Financial Group, INC now has 414,392 shares in the biopharmaceutical business after purchasing an additional 229,453 shares during the most recent quarter to bring their total number of shares to a total of 414,392.
These shares are currently valued at $146,000 as of right now.
The total value of Marshall Wace LLP’s new holding investment in Akebia Therapeutics was $101,000, and it was made during the third quarter of 2018.
During the first three months of 2018, Virtu Financial LLC spent $94,000 to increase its holdings in Akebia Therapeutics.
This was done as part of the company’s investment strategy.
During the first three months of the year, XTX Topco Ltd increased the proportion of Akebia Therapeutics’ shares that it owned by 282.7%. XTX Topco Ltd now has 102,392 shares of the biopharmaceutical company’s stock, currently valued at $74,000 after the company purchased an additional 75,635 shares during the period in question.
This brings the company’s total number of shares to 102,392.
Last but not least, during the first three months of this year, MetLife Investment Management LLC made a 176.6% increase in the amount of Akebia Therapeutics stock it owned, making it the largest single increase in the company’s ownership percentage.
After making additional purchases totaling 54,389 shares throughout the period, MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company.
The market price for these shares at the moment is $61,000. Hedge funds and other institutional investors hold 28.13 percent of the company’s stock.
When trading on AKBA started on Thursday, the stock was priced at $0.67.
The company’s price-to-earnings ratio is 1.29, and its beta value is 0.84.
The company is currently valued at $123.72 million by the market. Over the previous twelve months, a single share of Akebia Therapeutics has fluctuated between $0.24 and $2.60.
This stock’s moving average over the last 50 days comes in at $0.80, and its moving average over the last 200 days comes in at $0.50.
Patients experiencing problems with their kidneys are a target market for the biopharmaceutical company Akebia Therapeutics, INC, which is developing and marketing treatments for these patients.
In addition, the company researches, develops and brings pharmaceutical treatments for managing renal and metabolic diseases to market.
Auryxia and Vadadustat are two of the items that can be obtained through their use.